Erschienen:
Springer Science and Business Media LLC, 2020
Erschienen in:Veterinary Research
Sprache:
Englisch
DOI:
10.1186/s13567-020-00826-5
ISSN:
1297-9716
Entstehung:
Anmerkungen:
Beschreibung:
<jats:title>Abstract</jats:title><jats:p><jats:italic>Glaesserella parasuis</jats:italic> (<jats:italic>G. parasuis</jats:italic>) causes porcine vascular inflammation and damage. Baicalin is reported to have antioxidant and anti-inflammatory functions. However, whether baicalin protects piglets against <jats:italic>G. parasuis</jats:italic> challenge and the potential protective mechanism have not been investigated. Therefore, in this study, we comprehensively examined the protective efficacy of baicalin in piglets challenged with <jats:italic>G. parasuis</jats:italic> and the possible protective mechanism. Our results show that baicalin attenuated the release of the inflammation-related cytokines interleukin (IL) 1β, IL6, IL8, IL10, and tumour necrosis factor α (TNF-α) and reduced high mobility group box 1 (HMGB1) production and cell apoptosis in piglets infected with <jats:italic>G. parasuis</jats:italic>. Baicalin also inhibited the activation of the mitogen-activated protein kinase (MAPK) signalling pathway and protected piglets against <jats:italic>G. parasuis</jats:italic> challenge. Taken together, our data suggest that baicalin could protect piglets from <jats:italic>G. parasuis</jats:italic> by reducing HMGB1 release, attenuating cell apoptosis, and inhibiting MAPK signalling activation, thereby alleviating the inflammatory response induced by the bacteria. Our results suggest that baicalin has utility as a novel therapeutic drug to control <jats:italic>G. parasuis</jats:italic> infection.</jats:p>